Heartflow stock
HTFLNASDAQHeartflow, Inc., HealthcareISIN US42238D1072
46Score 46 out of 100, Weak
Price and trend
83 / 100
Price history
+68% in one yearThe chart shows daily closes over 1 year, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 71% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 56).
The price is 1.0% below its 52-week high. Largest decline in 1 year: 49% (October 2025 to March 2026).
Chart figures for advanced users
- SMA 50$51.94
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$35.12
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)56
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$20.49
- The lowest closing price of the last twelve months.
- Resistance$60.53
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Heartflow, Inc. belongs to the Medical (Healthcare Information Services) industry (United States) and, with a market value of $5.21B, is number 9 of 25 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $176.03M (up 39.9% year on year) and a loss of $116.79M.
- For fiscal 2026, analysts expect on average revenue of $248.62M (up 41.2%) and adjusted earnings per share of −$0.41.
Show more
- MEQIRI Score 46 out of 100 (Weak): rank 447 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $162.55M, financial debt $27.13M.Stability 53
Weaknesses
- Loss-makingLoss of $118.37M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$59.18M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 78% a year over the last 12 months.Stability 53
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 42.8% on the twelve months before. Revenue has grown strongly since 2023, at around 42% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 77%, operating −36%, net −66%. Last 12 months: net −56%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- No date announced.
- Last reported
- 12 Nov 2026EPS reported −$0.03 (expected −$0.10)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 5.1% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.41+0.1%
- Revenue
- $248.62M−0.1%
- Earnings per share
- −$0.27−5.1%
- Revenue
- $308.55M−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +41.0%Full-year outlook raised again: revenue of $246 million to $250 million (up 40% to 42%), Plaque revenue of $29 million to $31 million, non-GAAP gross margin of about 82%.
“We're now expected to deliver total revenue of $246 million to $250 million, representing 40% to 42% year-over-year growth. We're also raising our full-year 2026 Plaque revenue outlook to a range of $29 million to $31 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $20.98M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Farquhar John C.M.Sale
10 Nov 2026, Chief Executive Officer
- Shares
- 38,900
- Price
- $55.74
- Value
- $2.17M
- Verghese VikramSale
9 Nov 2026, Chief Financial Officer
- Shares
- 3,587
- Price
- $53.15
- Value
- $190,649
- Rogers CampbellSale
22 Oct 2026, Chief Medical Officer
- Shares
- 23,933
- Price
- $55.01
- Value
- $1.32M
Show 22 more
- Farquhar John C.M.Sale
12 Oct 2026, Chief Executive Officer
- Shares
- 38,900
- Price
- $49.57
- Value
- $1.93M
- Rogers CampbellSale
18 Sept 2026, Chief Medical Officer
- Shares
- 19,682
- Price
- $50.15
- Value
- $987,052
- Verghese VikramSale
18 Sept 2026, Chief Financial Officer
- Shares
- 16,766
- Price
- $50.75
- Value
- $850,926
- Verghese VikramSale
17 Sept 2026, Chief Financial Officer
- Shares
- 7,579
- Price
- $50.11
- Value
- $379,816
- Verghese VikramSale
15 Sept 2026, Chief Financial Officer
- Shares
- 668
- Price
- $50.01
- Value
- $33,408
- Verghese VikramSale
14 Sept 2026, Chief Financial Officer
- Shares
- 4,593
- Price
- $50.24
- Value
- $230,744
- Verghese VikramSale
11 Sept 2026, Chief Financial Officer
- Shares
- 29,714
- Price
- $50.06
- Value
- $1.49M
- Farquhar John C.M.Sale
11 Sept 2026, Chief Executive Officer
- Shares
- 3,890
- Price
- $50.00
- Value
- $194,500
- Farquhar John C.M.Sale
10 Sept 2026, Chief Executive Officer
- Shares
- 35,010
- Price
- $46.42
- Value
- $1.63M
- Verghese VikramSale
8 Sept 2026, Chief Financial Officer
- Shares
- 6,640
- Price
- $50.03
- Value
- $332,212
- Verghese VikramSale
3 Sept 2026, Chief Financial Officer
- Shares
- 27,540
- Price
- $49.69
- Value
- $1.37M
- Verghese VikramSale
2 Sept 2026, Chief Financial Officer
- Shares
- 5,876
- Price
- $50.60
- Value
- $297,326
- Farquhar John C.M.Sale
21 Aug 2026, Chief Executive Officer
- Shares
- 27,230
- Price
- $50.00
- Value
- $1.36M
- Farquhar John C.M.Sale
18 Aug 2026, Chief Executive Officer
- Shares
- 32,676
- Price
- $45.00
- Value
- $1.47M
- Rogers CampbellSale
17 Aug 2026, Chief Medical Officer
- Shares
- 9,219
- Price
- $41.23
- Value
- $380,099
- Farquhar John C.M.Sale
14 Aug 2026, Chief Executive Officer
- Shares
- 15,560
- Price
- $39.06
- Value
- $607,774
- Farquhar John C.M.Sale
10 Aug 2026, Chief Executive Officer
- Shares
- 22,562
- Price
- $28.31
- Value
- $638,730
- Rogers CampbellSale
15 Jul 2026, Chief Medical Officer
- Shares
- 9,219
- Price
- $25.72
- Value
- $237,113
- Farquhar John C.M.Sale
10 Jul 2026, Chief Executive Officer
- Shares
- 22,562
- Price
- $27.75
- Value
- $626,096
- Farquhar John C.M.Sale
24 Jun 2026, Chief Executive Officer
- Shares
- 38,900
- Price
- $35.00
- Value
- $1.36M
- Farquhar John C.M.Sale
10 Jun 2026, Chief Executive Officer
- Shares
- 22,562
- Price
- $28.50
- Value
- $643,017
- Rogers CampbellSale
18 May 2026, Chief Medical Officer
- Shares
- 9,219
- Price
- $28.34
- Value
- $261,266
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Heartflow
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 46
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- M32413.T $7.7B73
- Alibaba Health Information Technology0241.HK $6.19B60
- DoximityDOCS $5.92B81
- Waystar HoldingWAY $5.55B60
- Privia Health GroupPRVA $3.07B58
- CertaraCERT $1.79B54
- OmnicellOMCL $1.64B50
- Teladoc HealthTDOC $1.63B47
ETFs that hold Heartflow
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.14% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.14% | 0.30% | €4.22B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.05% | 0.30% | €185.82M |
Show 5 more
| Amundi MSCI Robotics & AI UCITS ETF AccGOAI | 0.05% | 0.40% | €1.14B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.04% | 0.43% | €2.48B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.19B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.